Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Friend-ly New Resource for Biomarker Validation?

This article was originally published in Start Up

Executive Summary

Merck is helping one of its top executives launch a new nonprofit venture, called Sage, which will develop disease models and provide an open access platform for researchers to gauge the effects of perturbing them. Pharma has never really supported the diagnostics industry apart from its own internal need for biomarkers. But along with supporting drug development, Sage could actually go to that very kind of diagnostics development that pharma has not wanted to do in the past.
Advertisement

Related Content

Is Diagnostics the New Biotech...and Will Pharma Embrace It?
BGI Touts Eventual Merck Deal
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
SatNav for Oncology Developers May Help Celleron Steer AZ's HDAC Inhibitor
New Initiatives to Improve Diagnostic Data Access
How to Earn the Economic Payback Diagnostics Companies Deserve
Enlight: Pharmas Collaborate on Novel Start-up
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Drug/Diagnostic Co-Development: When to Begin the Tandem Ride

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel